anticoagulant, curative dose for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients) NCT02735707		RCT	anticoagulant, curative dose	anticoagulant, prophylactic dose	COVID-19 mild to moderate	some concern	1190/1054	conclusif	demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias atypical endpoints without correspondence with those of the others trials
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients) NCT02735707		RCT	anticoagulant, curative dose	control	COVID-19 mild to moderate	some concern	1190/1054	conclusif	demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias atypical endpoints without correspondence with those of the others trials

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis